PDCD1 and hepatocellular carcinoma: Moreover, a recent study evaluated the use of cadonlimab, a bispecific antibody simultaneously binding to CTLA-4 and PD1, in combination with lenvatinib as a first-line treatment in patients with advanced HCC.